NEW YORK, Dec. 5, 2017 /PRNewswire/ -- The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed �" a requirement referred to as the ‘cold chain’. Read the full report: https://www.reportlinker.com/p03620308Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection.What You Will Learn• Provides detailed analysis of lyophilized drugs, as-supplied packaging and therapeutic indication• Analyzes therapeutic demand drivers and evaluates lyophilized drugs in eleven therapeutic areas• Analyzes lyophilization technologies and market development issues• Provides market data and forecasts to 2024• Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations• Assesses the importance of technology and regulatory factors on commercialization and market access Read the full report: https://www.reportlinker.com/p03620308
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected]
US: (339)-368-6001 Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/lyophilized-injectable-drugs-to-2024-300567376.html
SOURCE Reportlinker
